Overview
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Eligibility
Inclusion Criteria:
- Are candidates for systemic therapy.
ISA specific:
- Have moderate-to-severe AD, defined as meeting all of the following criteria, at the
first dosing visit:
- EASI score greater than or equal to (≥)16
- vIGA-AD score ≥3, and
- ≥10% of BSA involvement (per EASI BSA).
- Have applied at least 1 emollient every day for at least 2 weeks before the day of
the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study.
Exclusion Criteria:
ISA specific:
- Have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master IMMB.
- Are currently being treated with topical or systemic therapy
- Recent treatment with experimental (biologics and/or small molecules) - doesn't apply for subset of participants who must have been exposed to biologics and/or small molecules.